<DOC>
	<DOCNO>NCT00876733</DOCNO>
	<brief_summary>This observational study suppose ass ( condition clinical practice daily routine ) whether treatment Viramune ( nevirapine ) combination ARV , e.g . Combivir ( Zidovudine Lamivudine ) , Kivexa ( Abacavir Lamivudine ) Truvada ( tenofovir emtricitabine ) durably suppress viral load limit detection maintain suppression viral replication ( HIV-RNA limit detection ) achieve previous anti-retroviral combination therapy switch combination treatment Viramune ( nevirapine ) ARV , e.g . Combivir ( Zidovudine Lamivudine ) , Kivexa ( Abacavir Lamivudine ) Truvada ( tenofovir emtricitabine ) .</brief_summary>
	<brief_title>Non-Interventional Observational Study With Viramune Plus Antiretroviral HIV Infected Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<criteria>Inclusion criterion : male female 18 year old write informed consent The inclusion criterion treatment Viramune plus antiretroviral combination drug base current information healthcare professional / SmPC Exclusion criterion : Pregnant patient The exclusion criterion treatment Viramune plus antiretroviral combination drug base current SmPC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>